-+ 0.00%
-+ 0.00%
-+ 0.00%

Japanese Regulator Approves PTC Therapeutics' Sephience (Sepiapterin) For Phenylketonuria. The Label Includes Individuals Of All Ages And The Full Spectrum Of Disease Severity

Benzinga·12/22/2025 12:08:05
語音播報
  • PTC will now engage in pricing discussions which are expected to conclude in Q1 2026, with launch occurring shortly thereafter. 
  • First Japan product approval for PTC